Press release
Antonius Schuh Named CEO of TrovaGene, Inc. and Sets Sights on Novel Diagnostics with Trans-renal Technologies
SAN DIEGO -- TrovaGene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, has announced that Antonius Schuh, Ph.D. has been named Chief Executive Officer.Dr. Schuh previously served as Chairman and Chief Executive Officer of Sorrento Therapeutics, Inc. (Pink Sheets: SRNE.PK), a biotechnology company he co-founded based on a proprietary platform to generate very large fully human antibody libraries. Sorrento Therapeutics merged in 2009 with a public company supported by Phillip Frost and the Frost Group.
"I have observed TrovaGene closely over the past years, as I have been intrigued by the attractive opportunities the company's proprietary trans-renal technologies offer, and I am confident that we can introduce novel diagnostic modalities with significant clinical utility based on this platform," Dr.Schuh said.
Dr. Schuh also served as the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology. In 2008, Dr. Schuh led the sale of AviaraDx to bioMerieux, which continues to operate AviaraDx under the name bioTheranostics.
Before AviaraDx, Dr. Schuh served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus’ life science business to Molecular Devices, Inc. From 2000 to 2005, Dr. Schuh served as the President and Chief Executive Officer of Sequenom, Inc. (Nasdaq: SQNM).
He had joined Sequenom in 1996 as Managing Director of its European operations, and led during his tenure, amongst others, the commercial launch of the MassARRA® system and numerous business development and corporate acquisition transactions. Dr. Schuh holds a degree in pharmaceutics and earned his Ph.D. in medicinal chemistry from the University of Bonn, Germany.
Dr. Thomas Adams, TrovaGene's Chairman, welcomed Dr. Schuh's appointment.
“We are pleased and fortunate that Dr. Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise,” states Dr. Adams.
“The company has made significant efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring. Dr. Schuh has a proven track record of building companies and creating value for shareholders. I look forward to working with him.”
For further information, please contact:
Alex Michelini
Media Representative, TrovaGene, Inc.
.
(201) 831-0171
The Promotion Factory
5 E. 19th St., New York, NY 10003
T. 212-217-9065
Headquartered in San Diego, TrovaGene focuses on the development of its patented technology to detect trans-renal DNA and RNA, short nucleic acid fragments from normal and diseases cell death that cross the kidney barrier and can be detected in urine.
TrovaGene, Inc.
1105 Flintkote Ave., Suite B
San Diego, CA 92121
www.trovagene.com
Alex Michelini
212-217-9065
michelinialex@aol.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antonius Schuh Named CEO of TrovaGene, Inc. and Sets Sights on Novel Diagnostics with Trans-renal Technologies here
News-ID: 203395 • Views: …
More Releases from TrovaGene, Inc.
Trovagene Cited Among Top Molecular Diagnostic Developers
SAN DIEGO – Trovagene, Inc., a developer of transrenal molecular diagnostics, was placed in lofty company with Abbott Diagnostics and Rosetta Genomics in the increasingly important molecular diagnostics sector.
Mel Daris, a former mutual fund industry trader from Boston who currently trades independently, singled out the three companies in a Seeking Alpha report on the medical community’s expanding interest in molecular diagnostic testing.
“With advances in testing procedures, especially transrenal DNA…
Trovagene Called Well-Placed in Global Molecular Diagnostic Industry by NASDAQ
NEW YORK – Fresh from a successful public offering and new listing on the NASDAQ stock exchange, Trovagene CEO Antonius Schuh was given the honor of ringing the closing bell at Nasdaq’s Times Square marketsite. Standing in front of his management team, board of directors and special guests, Schuh reviewed Trovagene’s progress in developing faster, more accurate and less invasive diagnostics through urine analysis.
"Now we can watch how a cell…
Novel Urine Tests for Cancer Under Development to Replace Blood Samples
SAN DIEGO -- Scientists at Trovagene, Inc. (Pink Sheets: TROV.PK), a developer of trans-renal molecular diagnostics, are working to develop novel tests to detect tumor-derived DNA in cancer patients through a patient's urine, rather than blood samples.
"By the end of the year, we hope to introduce a novel k-RAS gene test that detects mutations in pancreatic and colon cancers," said Antonius Schuh, Trovagene's Chief Executive…
TrovaGene Expands Franchise of Proprietary Markers in Hematological Cancers With …
SAN DIEGO -- TrovaGene, Inc. (Pink Sheets: TROV), a developer of trans-renal molecular diagnostics, announced it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL).
The findings have been published in the Dec 22 issue of BLOOD, the journal of the American Society of Hematology, in…
More Releases for Schuh
Global Cam Switch Market Size, Share and Trends 2021-2027 | ABB, Schneider Elect …
Understand the influence of COVID-19 on the Cam Switch Market with our analysts monitoring the situation across the globe.
Report Description:
Market Strides published report titled Cam Switch Market By Type, By Application, Regional Analysis, Growth Opportunity and Industry Forecast 2021-2027. The Cam Switch Market Report provides a comprehensive overview including Current scenario and the future growth prospects. The Cam Switch market report analyzes the various factors and trends in forthcoming years…
SGS to Attend Expo Riva Schuh Footwear Exhibition in India
The Expo Riva Schuh India is a new exhibition event that goes beyond the mere display of products: it is the first trade show in India entirely dedicated to footwear and leatherwear. Supported by the Indian Trade Promotion Organisation (ITPO), the event represents a unique opportunity to get a better insight into the specific tools and rules required to operate on the local market.
The first edition of Expo Riva Schuh…
ACTLean and Schuh & Company Announce Lean Bronze Certification Workshop in Atlan …
With an established Lean Certification Standard, companies can make Lean activities an integral part of the organization. Professionals attain industry recognized abilities that make them stand out in the crowd.
Lawrenceville, GA, July 22, 2011 – ACTLean will offer a 1.5 day Lean Bronze Certification Workshop and a half day Lean Bronze Certification Exam in Atlanta, GA and Miami, FL. ACTLean also offers customized Lean Bronze Certifications workshops…
ACTLean and Schuh & Company Announce Lean Bronze Certification Workshop in Atlan …
With an established Lean Certification Standard, companies can make Lean activities an integral part of the organization. Professionals attain industry recognized abilities that make them stand out in the crowd.
Lawrenceville, GA, March 30, 2011– ACTLean will offer a 1.5 day Lean Bronze Certification Workshop and a half day Lean Bronze Certification Exam in Atlanta, Ga on May 26th and 27th, 2011.
With the Lean Bronze Certification, Lean practitioners demonstrate…
ACTLean and Schuh & Company Announce Lean Bronze Certification Workshop in Spart …
Lawrenceville, GA, January 17, 2011– ACTLean will offer a 1.5 day Lean Bronze Certification Workshop and a half day Lean Bronze Certification Exam in Spartanburg, SC on March 10th and 11th, 2011.
With the Lean Bronze Certification, Lean practitioners demonstrate a solid understanding of basic lean principles and tools, as well as their ability in tactical implementation projects that drive improvements and show measurable results.
To achieve Lean Bronze Certification, participants…
ACTLean and Schuh & Company Now Recognized as Approved Lean Bronze Certification …
Lawrenceville, GA, November 24, 2010 – ACTLean and Schuh & Company are pleased to announce their approval by the Society of Manufacturing Engineers (SME) as a Lean Bronze Certification Review Facilitator and Trainer.
Lean Certification is a benchmark for achievement and personal growth in Lean. Designed by three organizations – the Society of Manufacturing Engineers (SME), the Association for Manufacturing Excellence (AME) and The Shingo Prize for…
